Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005;353(16):1 Sung H, Ferlay J, Siegel RL, Laversanne M, Soer.

Article  Google Scholar 

Fulford LG, Easton DF, Reis-Filho JS, Sofronis A, Gillett CE, Lakhani SR, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology. 2006;49(1):22–34.

Article  CAS  PubMed  Google Scholar 

Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res. 2004;6:229–39.

Article  PubMed  PubMed Central  Google Scholar 

WHO. Cancer Afghanistan. 2020 country profile [Internet]. 2020. [cited 2022 Nov 20]. Available from: https://cdn.who.int/media/docs/default-source/country-profiles/cancer/afg_2020.pdf.

Sree SV. Breast imaging: a survey. World J Clin Oncol. 2011;2(4):1 Sung H, Ferlay J, Siegel RL, Laversanne M, Soer.

Article  Google Scholar 

Saadaat R, Abdul-Ghafar J, Haidary AM, Rahmani S, Atta N. Age distribution and types of breast lesions among Afghan women diagnosed by fine needle aspiration cytology (FNAC) at a tertiary care centre in Afghanistan: a descriptive cross-sectional study. BMJ Open. 2020;10(9):1–5.

Article  Google Scholar 

American Cancer Society. Breast cancer early detection and diagnosis American Cancer Society recommendations for the early detection of breast cancer. Am Cancer Soc. 2016:1–55. Available from: https://www.cancer.org/content/dam/CRC/PDF/Public/8579.00.pdf.

Poorolajal J, Nafissi N, Akbari ME, Mahjub H, Esmailnasab N, Babaee E. Breast cancer survival analysis based on immunohistochemistry subtypes (ER/PR/HER2): a retrospective cohort study. Arch Iran Med. 2016;19(10):680–6.

PubMed  Google Scholar 

Mujtaba S, Haroon S, Faridi N, Rashid LF. Correlation of human epidermal growth factor receptor 2 (HER-2/neu) receptor status with hormone receptors Oestrogen Receptor, Progesterone Receptor status and other prognostic markers in breast cancer: An experience at tertiary care hospital in Karachi. J Pak Med Assoc. 2013;63(7):854–8.

PubMed  Google Scholar 

DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62.

Article  PubMed  Google Scholar 

Gore CR, Gurwale S, Sammi A, Dey I, Deshpande AH. Estrogen, progesterone, and human epidermal growth factor receptor-2 in malignant breast lesions. Med J Dr DY Patil Vidyapeeth. 2018;11(1):9–15.

Google Scholar 

Pourzand A, Fakhree MBA, Hashemzadeh S, Halimi M, Daryani A. Hormone receptor status in breast cancer and its relation to age and other prognostic factors. Breast Cancer Basic Clin Res. 2011;5(1):87–92.

Google Scholar 

Magaki S, Hojat SA, Wei B, So A, Yong WH. An introduction to the performance of immunohistochemistry. Methods Mol Biol. 2019;1897:289–98.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nakata T, Suzuki N. Chromogen-based immunohistochemical method for elucidation of the coexpression of two antigens using antibodies from the same species. J Histochem Cytochem. 2012;60(8):611–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Longacre TA, Broaddus R, Chuang LT, Cohen MB, Jarboe EA, Mutter GL, et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the endometrium. Arch Pathol Lab Med. 2017;141(11):1508–12.

Article  PubMed  Google Scholar 

Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118–45.

Article  CAS  PubMed  Google Scholar 

Almumen M. Immunohistochemical expression of VEGF in relation to other pathological parameters of breast carcinoma. J Cancer Ther. 2015;06(09):811–20.

Article  CAS  Google Scholar 

Meyer JS, Alvarez C, Milikowski C, Olson N, Russo I, Russo J, et al. Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: Reproducibility of grade and advantages of proliferation index. Mod Pathol. 2005;18(8):1067–78.

Article  PubMed  Google Scholar 

Roshed MM, Kamal S, Hossain SM, Akhtar S. Evaluation of breast cancer subtypes based on ER/PR and Her2 expression: a clinicopathologic study of hormone receptor status (ER/PR/HER2-neu) in breast cancer. Faridpur Med Coll J. 2020;14(1):8–12.

Article  Google Scholar 

Aman NA, Doukoure B, Koffi KD, Koui BS, Traore ZC, Kouyate M, et al. HER2 overexpression and correlation with other significant clinicopathologic parameters in ivorian breast cancer women 11 medical and health sciences 1112 oncology and carcinogenesis. BMC Clin Pathol. 2019;19:1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sohail SK, Sarfraz R, Imran M, Kamran M, Qamar S. Estrogen and Progesterone Receptor Expression in Breast Carcinoma and Its Association With Clinicopathological Variables Among the Pakistani Population. Cureus. 2020;12(8):e9751. https://doi.org/10.7759/cureus.9751.

Wolff MS, Weston A. Breast cancer risk and environmental exposures. Environ Health Perspect. 1997;105(SUPPL. 4):891–6.

CAS  PubMed  PubMed Central  Google Scholar 

Bowen DJ, Poole SF, White M, Lyn R, Flores DA, Haile HG, et al. The role of stress in breast cancer incidence: risk factors, interventions, and directions for the future. Int J Environ Res Public Health. 2021;18(4):1–15.

Article  Google Scholar 

Koval LE, Dionisio KL, Friedman KP, Isaacs KK, Rager JE. Environmental mixtures and breast cancer: identifying co-exposure patterns between understudied vs breast cancer-associated chemicals using chemical inventory informatics. J Expo Sci Environ Epidemiol. 2022;32(6):794–807.

Article  PubMed  PubMed Central  Google Scholar 

Ursin G, Bernstein L, Lord SJ, Karim R, Deapen D, Press MF, et al. Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology. Br J Cancer. 2005;93(3):364–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kelsey JL, Gammon MD, John EM. Reproductive factors and breast. Cancer. 1993;15(1):1 Sung H, Ferlay J, Siegel RL, Laversanne M, Soer.

Google Scholar 

Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press). 2019;11:151-64. https://doi.org/10.2147/BCTT.S176070.

Heller JR. National cancer institute. J Am Med Assoc. 1951;146:1248.

Article  Google Scholar 

Sopik V, Narod SA. The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. Breast Cancer Res Treat. 2018;170(3):647–56. https://doi.org/10.1007/s10549-018-4796-9.

Article  PubMed  PubMed Central  Google Scholar 

Bansal C, Sharma A, Pujani M, Pujani M, Sharma KL, Srivastava AN, et al. Correlation of hormone receptor and human epidermal growth factor Receptor-2/neu expression in breast cancer with various clinicopathologic factors. Indian J Med Paediatr Oncol. 2017;38(4):483–9.

Article  PubMed  PubMed Central  Google Scholar 

Cserni G. Tumour histological grade may progress between primary and recurrent invasive mammary carcinoma. J Clin Pathol. 2002;55(4):293–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hermansyah D, Pricilia G, Azrah A, Rahayu Y, Paramita DA, Siregar ES. Correlation between grading histopathology and sentinel lymph node metastasis in early breast cancer in university of sumatera utara hospital. Open Access Maced J Med Sci. 2021;9:679–82.

Article  Google Scholar 

Collins JA, Blake JM, Crosignani PG. Breast cancer risk with postmenopausal hormonal treatment. Human Reprod Update. 2005;11:545–60.

Article  CAS  Google Scholar 

Martin AM, Weber BL. Genetic and hormonal risk factors in breast cancer. J Natl Cancer Inst. 2000;92(14):1126–35.

Article  CAS  PubMed  Google Scholar 

Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999–2004. Breast J. 2009;15(6):593–602.

Article  PubMed  Google Scholar 

Ayadi L, Khabir A, Amouri H, Karray S, Dammak A, Guermazi M, et al. Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma. World J Surg Oncol. 2008;22:6.

Google Scholar 

Shaikh F, Jamal Q, Baig S, Hadi NI, Majeed N. Correlation of hormone receptor and HER-2/neu expression with clinicopathologic parameters in primary breast tumors. Asian Pacific J Cancer Prev. 2016;17(7):3363–7.

Google Scholar 

Yadav R, Sen R, Chauhan P. ER, PR, HER2/NEU status and relation to clinicopathological factors in breast carcinoma. Int J Pharm Pharm Sci. 2016;8(4):287–90.

CAS  Google Scholar 

Hussain A. Correlations of Hormone Receptors (ER and PR), Her2/neu and p53 Expression in Breast Ductal Carcinoma Among Yemeni Women. The Open Cancer Immunology Journal. 2011;4:1-9. https://doi.org/10.2174/1876401001104010001.

Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009;7(1-2):4-13. https://doi.org/10.3121/cmr.2009.825.

Pajenga E, Rexha T, Çeliku S, Ugrinska A, Bejtja G. Hormonal receptor, human epidermal growth factor and its association with breast cancer tumor characteristics in Albania. Cent Eur J Public Health. 2016;24(3):171–5.

Article  CAS  PubMed  Google Scholar 

Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, et al. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol. 2005;58(6):611–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lakshmi A. A study of correlation of expression of ER, PR and HER2/neu receptor status with clinico-pathological parameters in breast carcinoma at a tertiary care centre. Int J Res Med Sci. 2015;1.

Prat A, Cheang MCU, Martín M, Parker JS, Carrasco E, Caballero R, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal a breast cancer. J Clin Oncol. 2013;31(2):203–9.

Article  CAS  PubMed  Google Scholar 

Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21(10):1973–9.

Article  CAS  PubMed